This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Look at the use of Abbvie's Humira as an approved treatment for Hidradenitis Suppurativa and the landscape of potential new treatments on the horizon
Ticker(s): ABBV, NVSWho's the expert?
Institution: Dermatology Associates of Western Connecticut.
- Dr. Knispel is a Fellow of the American Academy of Dermatology, as well as a member of the Connecticut Dermatology & Dermatologic Surgery Society, the New England Dermatologic Society, the Fairfield County Medical Association, and the Connecticut State Medical Society. Currently, he is on staff at Danbury Hospital and New Milford Hospital. He also holds the position of Assistant Clinical Professor of Dermatology in the Yale University School of Medicine.
- Manages 500 atopic dermatitis patients.
- Very familiar with the ox-40 data.
Interview GoalDiscussing the the standard of care and the competitive landscape between ABBV Humira and NVS Cosentyx, as well as the clinical studies of treatments such as ANAB imsidolimab.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
